Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMCIRAV: Gemcitabine, Cisplatin, and Radiotherapy in Bladder Cancer
NCT00556621Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jun 2005
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in bladder cancer, sponsored by Institut du Cancer de Montpellier. Primary endpoints: Incidence and nature of acute and late toxicity and Local tumor control (absence of local progression). Started Jun 2005; status: completed.
02
Drugs
gemcitabine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00556621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556621.